BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kondo Y, Kikuchi T, Esteban JC, Kumaki N, Ogura G, Inomoto C, Hirabayashi K, Kajiwara H, Sakai A, Sugimoto R, Otsuru M, Okami K, Tsukinoki K, Nakamura N. Intratumoral heterogeneity of HER2 protein and amplification of HER2 gene in salivary duct carcinoma. Pathol Int 2014;64:453-9. [PMID: 25209856 DOI: 10.1111/pin.12195] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Egebjerg K, Harwood CD, Woller NC, Kristensen CA, Mau-Sørensen M. HER2 Positivity in Histological Subtypes of Salivary Gland Carcinoma: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:693394. [PMID: 34249747 DOI: 10.3389/fonc.2021.693394] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
2 Malignant Epithelial Neoplasms. Tumors of the Salivary Glands 2021. [DOI: 10.55418/9781933477947-06] [Reference Citation Analysis]
3 Gnepp DR, Skalova A, Palma SD, Simpson RH, Nagao T, Bilodeau EA. Salivary Glands. Gnepp's Diagnostic Surgical Pathology of the Head and Neck 2021. [DOI: 10.1016/b978-0-323-53114-6.00006-7] [Reference Citation Analysis]
4 Kondo Y, Hirabayashi K, Carreras J, Tsukinoki K, Ota Y, Okami K, Nakamura N. The significance of tyrosine kinase receptor B and brain-derived neurotrophic factor expression in salivary duct carcinoma. Ann Diagn Pathol 2021;50:151673. [PMID: 33248386 DOI: 10.1016/j.anndiagpath.2020.151673] [Reference Citation Analysis]
5 Longo R, Legros PO, Talbi M, Wagner M, Paraschiv EA, Campitiello M, Plastino F, Rozzi A. HER2-positive metastatic, parotid salivary duct carcinoma treated with a trastuzumab/pertuzumab-based chemotherapy: A case report. Clin Case Rep 2020;8:2878-82. [PMID: 33363842 DOI: 10.1002/ccr3.3209] [Reference Citation Analysis]
6 Yan W, Hu H, Tang B. Advances Of Chimeric Antigen Receptor T Cell Therapy In Ovarian Cancer. Onco Targets Ther 2019;12:8015-22. [PMID: 31686857 DOI: 10.2147/OTT.S203550] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
7 Son E, Panwar A, Mosher CH, Lydiatt D. Cancers of the Major Salivary Gland. J Oncol Pract 2018;14:99-108. [PMID: 29436307 DOI: 10.1200/JOP.2017.026856] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 7.3] [Reference Citation Analysis]
8 Kanazawa T, Misawa K, Fukushima H, Misawa Y, Sato Y, Maruta M, Imayoshi S, Kusaka G, Kawabata K, Mineta H, Carey TE, Nishino H. Epigenetic inactivation of galanin receptors in salivary duct carcinoma of the parotid gland: Potential utility as biomarkers for prognosis. Oncol Lett 2018;15:9043-50. [PMID: 29805635 DOI: 10.3892/ol.2018.8525] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
9 Schmitt NC, Kang H, Sharma A. Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy. Oral Oncol 2017;74:40-8. [PMID: 29103750 DOI: 10.1016/j.oraloncology.2017.09.008] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 8.0] [Reference Citation Analysis]
10 Chung CH, Germain A, Subramaniam RM, Heilmann AM, Fedorchak K, Ali SM, Miller VA, Palermo RA, Fakhry C. Genomic alterations in human epidermal growth factor receptor 2 ( HER2/ERBB2 ) in head and neck squamous cell carcinoma: HER2 alterations in HNSCC. Head Neck 2017;39:E15-9. [DOI: 10.1002/hed.24587] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
11 Panwar A, Kozel JA, Lydiatt WM. Cancers of major salivary glands. Surg Oncol Clin N Am 2015;24:615-33. [PMID: 25979403 DOI: 10.1016/j.soc.2015.03.011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
12 Gomes CC, Galvão CF, do Carmo ACDM, Pereira NB, Gomez RS. Intratumor molecular heterogeneity in pleomorphic adenoma of the salivary glands. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 2016;121:158-63. [DOI: 10.1016/j.oooo.2015.09.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
13 Hedner C, Tran L, Borg D, Nodin B, Jirström K, Eberhard J. Discordant human epidermal growth factor receptor 2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis. Histopathology 2016;68:230-40. [DOI: 10.1111/his.12744] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]